Research into GSK-3 inhibition in cells may have implications for leukemia treatment.
In previous research, Peter Klein, MD, from the University of Pennsylvania, had found that one of lithium’s biological activities was inhibiting GSK-3. Klein recently investigated what proteins in the cell are affected by GSK-3 inhibition by comparing cells with GSK-3 to those lacking GSK-3, and the findings have implications for understanding leukemia.
The study, published in the Journal of Biological Chemistry, used mass spectrometry to compare phosphorylation of proteins from mouse embryonic stem cells with functioning GSK-3 to cells where the gene encoding GSK-3 had been deleted. From this, the researchers analyzed the phosphoproteome dataset, a catalog of proteins that are phosphorylated by GSK-3.
“Mood disorders are so multifaceted in terms of the pathways and pathologies involved; it's really difficult to pin down a specific pathway,” stated Mansi Shinde, PhD, a former graduate student in Klein’s research group who led the new study. “We said: Let's look at what GSK-3 does, and that would maybe lead us toward what lithium does.”
The analysis revealed that the majority of proteins whose phosphorylation depended on GSK-3 did not contain the specific amino acid sequence that GSK-3 phosphorylate proteins typically contain. The phosphorylated proteins had a group of splicing factors, which spice different sections of messenger RNA and change the proteins that they encode, according to the study.
The finding that GSK-3 could affect RNA splicing revealed a connection to leukemia, as many factors discovered to be phosphorylated by GSK are also mutated in acute myeloid leukemia. The researchers inferred that this could explain why increased white blood cell count is a side effect of taking lithium.
“The relevance to leukemia could be direct and something worthy of immediate study,” Klein said. “The role in psychiatric disorders is a major interest of the work, but the impact would be down the road, not immediate.”
The researchers are now looking to investigate how GSK-3 affects the growth of healthy and leukemic blood cells. Therefore, the effect of GSK-3 on messenger RNA in neuronal cells, with or without lithium needs to be examined.
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
October 21st 2024Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Read More
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More